Rucaparib monocamsylate

Overview

Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K i of 1.4 nM for PARP1 . Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research.

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PARP

Product Information

• Catalog No.: HY-102003
• CAS No.: 1859053-21-6
• Molecular Formula: C29H34FN3O5S
• Molecular Weight: 555.66
• Purity: 99.91%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.08 mg/mL (3.74 mM); Clear solution
• Availability: In-stock

Source

Original product source